Tag: Biosciences
Shanghai Junshi Biosciences Co., Ltd. : UBS reiterates its positive opinion on the stock
Marketzone with MT Newswires 2022 All news about SHANGHAI JUNSHI BIOSCIENCES CO., LTD. Financial data CNYUSDUSD 2022 turnover 2,444M…
Neurocrine Biosciences, Inc.: Goldman Sachs Still Positive
Marketzone with MT Newswires 2022 All the news about NEUROCRINE BIOSCIENCES, INC. Analyst Recommendations for NEUROCRINE BIOSCIENCES, INC. 2022…
Codiak BioSciences, Inc.: Positive Opinion of Goldman Sachs
Marketzone with MT Newswires 2022 All the news about CODIAK BIOSCIENCES, INC. Analyst Recommendations on CODIAK BIOSCIENCES, INC. 2022…
NFL BIOSCIENCES: PARTICIPATION IN THE HCWAINWRIGHT 1ST ANNUAL MENTAL HEALTH CONFERENCE – 06/24/2022 at 18:00
NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of dependencies and addictions, announces that Ignacio Faus, CEO of NFL Biosciences…
NFL BIOSCIENCES: Decision to grant its patent in South Korea – 05/11/2022 at 18:15
NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of dependencies and addictions, announces that it has received approval from the…
NFL Biosciences: decision to grant its patent in China
By Hector Chaunu Published on 04/11/2022 at 6:34 p.m. Photo credit © Reuters …
Sanofi raises its Dupixent sales target to more than 13 billion euros, signs an agreement with IGM Biosciences
(Reuters) – Sanofi announced on Tuesday, before the opening of an investor day dedicated to its immunology portfolio, a revision of its business objective for its now expected asthma and…
NFL Biosciences: Activities & Annual results 2021 – 03/28/2022 at 07:00
NFL Biosciences: Activities & 2021 Annual Results Implementation of the Phase II/III clinical study of the drug candidate NFL-101 for smoking cessation: first patients recruited and increase in recruitment capacity…
NFL Biosciences soars on the stock market after a co-development agreement for its drug candidate NFL-301
The biopharmaceutical company announces a co-development agreement for its drug candidate NFL-301, intended to reduce alcohol consumption. NFL Biosciences takes off on the stock market after a co-development agreement for…
NFL Biosciences collaborates with Athena Pharmaceuticals for its drug candidate NFL-301
Subscribe for 1€ Unlimited access to all advice More than 800 stocks listed in Paris and abroad screened. To buy ? To sell ? What course objective? Our experts engage…
Castle Biosciences, Inc .: Stephens Inc. remains for purchase
Zonebourse with MT Newswires 2022 All the news on CASTLE BIOSCIENCES, INC. Analyst Recommendations on CASTLE BIOSCIENCES, INC. Turnover 2021 92.3 M – 81.3 M 2021 net result -37.2 M…